A therapeutic system for supplying active substances to the skin consists of a backing layer remote from the skin, with at least one active substance depot. The depot may consist of a fluid active substance or a fluid composition comprising an active substance delivery control matrix. There is also included an adhesive fixing device for fixing the therapeutic system on the skin. The therapeutic system is characterized in that the active substance depots (14) consist of at least one adjuvant having a supporting and distributing function by being provided with a planar textile material completely surrounded by matrix (12).
|
0. 61. A sealing bag for an active substance that can be applied in a transdermal manner comprising an acrylonitrile methyl acrylate copolymer containing medicament barrier layer and an aluminum-containing medicament-degradation agent barrier.
7. A sealing bag containing a nicotine patch comprising a four edged sealing bag made of a composite comprising paper, aluminum and a butadiene-acrylonitrile modified acrylonitrile methyl acrylate copolymer, and wherein the nicotine patch is contained within said bag.
0. 26. A sealing bag containing a nicotine patch comprising a bag sealed on all edges made of a composite comprising an aluminum layer and a butadiene-acrylonitrile modified acrylonitrile methyl acrylate copolymer layer, wherein the nicotine patch is contained within said bag.
0. 37. A bag for a patch with an active substance comprising a sealing bag made of a composite comprising an aluminum layer and a butadiene-acrylonitrile modified acrylonitrile methyl acrylate copolymer layer wherein the patch with the active substance is contained within said bag.
9. A sealing bag containing a nicotine patch comprising a four edged sealing bag made of a composite consisting of paper, aluminum and a thermoplastic butadiene-acrylonitrile modified acrylonitrile methyl acrylate copolymer, and wherein the nicotine patch is contained within said bag.
0. 54. A bag for a nicotine patch comprising a sealing bag made of a composite comprising an aluminum layer and a butadiene-acrylonitrile modified acrylonitrile methyl acrylate copolymer layer wherein said layers are in contact with each other and the nicotine patch is contained within said bag.
0. 27. A sealing bag consisting of a combination of
a) a thermoplastic butadiene-acrylonitrile modified acrylonitrile methyl acrylate copolymer layer, and b) an aluminum layer, wherein said layers form a bag which is sealed on all edges and a nicotine patch is contained within said bag.
0. 28. A sealing bag containing a nicotine patch comprising a bag sealed on all edges comprising a composite consisting essentially of an aluminum layer and a thermoplastic butadiene-acrylonitrile modified acrylonitrile methyl acrylate copolymer layer, wherein the nicotine patch is contained within said bag.
0. 25. A sealing bag containing a nicotine patch comprising a combination of
a) a butadiene-acrylonitrile modified acrylonitrile methyl acrylate copolymer layer, and b) a layer comprising aluminum, wherein the layers form a bag which is sealed on all edges and the nicotine patch is contained within said bag.
0. 36. A sealing bag containing a nicotine patch comprising a bag sealed on all edges comprising a composite consisting essentially of a paper layer, an aluminum layer and a thermoplastic butadiene-acrylonitrile modified acrylonitrile methyl acrylate copolymer layer, wherein the nicotine patch is contained within said bag.
0. 45. A sealing bag containing a nicotine patch comprising a bag sealed on all edges made of a composite comprising an aluminum layer and a butadiene-acrylonitrile modified acrylonitrile methyl acrylate copolymer layer, wherein said layers are in contact with each other and the nicotine patch is contained within said bag.
8. A sealing bag consisting of:
a) a thermoplastic butadiene-acrylonitrile modified acrylonitrile methyl acrylate copolymer layer, and b) a composite layer consisting of paper and aluminum, c) wherein the layers from a bag which is sealed on four edges, and d) wherein a nicotine patch is contained within said bag.
0. 46. A sealing bag consisting of a combination of
a) a thermoplastic butadiene-acrylonitrile modified acrylonitrile methyl acrylate copolymer layer, and b) an aluminum layer, wherein the layers are in contact with each other and form a bag which is sealed on all edges and a nicotine patch is contained within said bag.
0. 57. A bag for a nicotine patch comprising a sealing bag made of a composite comprising a degradation agent barrier layer for said nicotine patch and a butadiene-acrylonitrile modified acrylonitrile methyl acrylate copolymer layer wherein said layers are in contact with each other and a nicotine patch is contained within said bag.
1. A sealing bag containing a nicotine patch comprising:
a) a butadiene-acrylonitrile modified acrylonitrile methyl acrylate copolymer layer, and b) a composite layer comprising paper and, aluminum, c) wherein the layers form a bag which is sealed on four edges, and d) wherein a nicotine patch is contained within said bag.
0. 47. A sealing bag containing a nicotine patch comprising a bag sealed on all edges comprising a composite consisting essentially of an aluminum layer and a thermoplastic butadiene-acrylonitrile modified acrylonitrile methyl acrylate copolymer layer, wherein said layers are in contact with each other and the nicotine patch is contained within said bag.
0. 41. A bag for a patch with an active substance comprising a sealing bag made of a composite comprising a degradation agent barrier layer for said active substance and a butadiene-acrylonitrile modified acrylonitrile methyl acrylate copolymer layer wherein said layers are in contact with each other and the active substance is contained in the patch within said bag.
0. 53. A sealing bag containing a nicotine patch comprising a bag sealed on all edges comprising a composite consisting essentially of a paper layer, an aluminum layer and a thermoplastic butadiene-acrylonitrile modified acrylonitrile methyl acrylate copolymer layer, wherein said layers are in contact with each other and the nicotine patch is contained within said bag.
2. A sealing bag according to
3. The sealing bag of
4. The sealing bag of
5. The sealing bag of
6. The sealing bag of
10. A sealing bag according to
11. The sealing bag of
12. The sealing bag of
13. The sealing bag of
14. The sealing bag of
15. A sealing bag according to
16. The sealing bag of
17. The sealing bag of
18. The sealing bag of
19. The sealing bag of
20. A sealing bag according to
21. The sealing bag of
22. The sealing bag of
23. The sealing bag of
24. The sealing bag of
0. 29. A sealing bag as claimed in
0. 30. A sealing bag as claimed in
0. 31. A sealing bag as claimed in
0. 32. A sealing bag as claimed in
0. 33. A sealing bag as claimed in
0. 34. A sealing bag as claimed in
0. 35. A sealing bag as claimed in
0. 38. The bag according to
0. 39. The bag according to
0. 40. The bag according to
0. 42. The bag according to
0. 43. The bag according to
0. 44. The bag according to
0. 48. A sealing bag as claimed in
0. 49. A sealing bag as claimed in
0. 50. A sealing bag as claimed in
0. 51. A sealing bag as claimed in
0. 52. A sealing bag as claimed in
0. 55. The bag according to
0. 56. The bag according to
0. 58. The bag according to
0. 59. The bag according to
0. 60. The bag according to
0. 62. The sealing bag of
0. 63. The sealing bag of
0. 64. The sealing bag of
0. 65. The sealing bag of
0. 66. The sealing bag of
0. 67. The sealing bag of
0. 68. The sealing bag of
|
The process for producing the system according to
Typical thicknesses for inventive transdermal systems are in the case of a total thickness of approximately 123 to 5550 μm, preferably 285 to 1550 μm; thickness of the backing layer 8 to 150 μm and preferably 15 to 100 μm; thickness of the reservoir 100 to 5000 μm, preferably 200 to 1330 μm; thickness of the protective layer 15 to 400 μm, preferably 70 to 150 μm.
For special application it is also possible to market the "semifinished product" as such, so as to enable users to carry out the separation of the systems, so that the semifinished product acts in the manner of a "storage pack".
Preferred examples of the invention are described below.
Nicotine plasters, such as are used to stop people from smoking, are, according to the invention, produced as follows.
A pressure sensitive adhesive material comprising 2.0825 kg of a 40% solution of a self-crosslinking acrylate copolymer, e.g. of 2-ethyl-hexyl acrylate, vinyl acetate, acrylic acid and titanium chelate ester, or DUROTAC 280-2416 of the firm National Starch/Chemical B.V. in a mixture of ethyl acetate, ethanol, hexane and methanol, 147 g of an acrylic resin of dimethylaminoethylmethacrylate and neutral methacrylate (EUDRAGIT E 100 of the firm RÖHM PHARMA), and 20 g of a mixed acidic triglyceride of fractionated C8-C10 coconut fatty acids (Miglyol 812 of the firm Dynamit Nobel) are applied to a protective layer vapor-deposited with aluminum on one side and abhesively finished on both sides and the solvent is evaporated at 50°C to 80°C C. An approximately 300 g/m2 layer is obtained. From the thus produced pressure sensitive adhesive layer are punched round discs with a diameter of 65 mm. The projecting edges are worked and central to the same is applied in each case one circular disc of a non-woven fabric e.g. fibrous mixture of viscose staple cotton fiber 50:50 with a substance weight of 80 g/m2 and with a diameter of 40 mm. An example of such a product is PARATEX II/80, a product of LOHMANN GMBH & CO KG. PARATEX is a registered trademark of Lohmann GmbH & Co. KG. To this is applied nicotine as the active substance in solution (140 g nicotine in 100 g of an acrylic resin of dimethylaminoethylmethacrylate and neutral methacrylates (EUDRAGIT E 100 of the Firm RÖHM PHARMA) in 102 mg doses/disc. The thus produced patches are immediately laminated with a nicotine impermeable backing layer(a 15 μm thick polyester film on one side of which aluminum is vapor deposited) and sealed in four-edge sealing bags of a suitable packing material. The depot side of the backing layer may be layered with a layer of approximately 300 g/m2 of the pressure sensitive adhesive layer, referred to above. The four-edge sealing bags may consist of a compound of paper (surface weight 50 g/m2), aluminum 9 μm and Barex (trademark of the firm Vistron Corp., Cleveland, Ohio, USA, for thermoplastic acrylonitrile-copolymers with negligible gas permeability and great resistance to solvents) with 26 g/m2. Thus, those nitrile rubber modified acrylonitrile-methylacrylate copolymers serve as nicotine barrier layer, the aluminium as a nicotine degradation agent barrier, and the paper as a protective layer.
In the case of this example the non-woven fabric serves as the supporting fabric and to assist the uniform distribution of the nicotine as an inert adjuvant as defined hereinbefore.
The chemical composition of Barex has been known to the public, as is evident from the publication of M.TH. Schuler in "Kunststoffe-Plastics" 9/1974, pages 13-20. Particular reference is made to the title, page 13, left-hand column, lines 1 to 3 which both refer generally to "Barex-Harze", page 14/14-16, page 17, right-hand column, section "Untersuchungen an Barex zur Zulassung durch die FDA", lines 5-7 and page 18, column 2, paragraph 2 referring to the approval of the US FDA and stating that Barex (without specific reference to Barex 210) is obtained by graft polymerisation (Pfropf-Polymerisation) of 73-77 parts of acrylonitrile and 23-27 parts of methyl acrylate in the presence of 8-10 parts butadiene-acrylonitrile copolymer of 70% of butadiene, the parts and percents always being by weight. Moreover, the fact that Barex is a thermoplastic copolymer which has negligible gas permeability and good resistance to solvents is, for example, evident from page 13, left-hand column, paragraph 1. Line 1 specifically recites thermoplastic, while the sentence starting in line 5 reads in translation as follows:
"As already the term "barring plastic" means, this novel material has very good barring properties against various gases such as oxygen, carbon dioxide (carbonic acid), nitrogen and also many chemical agents such as acids, alkalis and solvents".
The next sentence refers to the copolymerization of acrylonitrile with selected monomers. Lines 7 to 13 of paragraph 2 of left-hand column of page 13 read in translation:
"Its (i.e. of Barex 210) permeability for oxygen and carbon dioxide is about ten times smaller than that of other conventional bulk plastics. This modern plastic is particularly suitable for applications in which glass-like clarity, prevention of loss of flavor and gas-impermeability are required."
As used herein, the term "sealing bag" refers to a package or other container which is generally flexible and is sealed on at least one side. The sealing bags of this invention can comprise, for example, two sheets or lamina which have been joined along all edges; a single sheet or lamina which has been folded and sealed along all edges or along all non-folded edges; a pouch or pocket which is sealed along one or more edges; and the like.
The term "nicotine barrier" as used herein, implies that the barrier material is inert to nicotine and does not permit nicotine to migrate through the material over a nicotine barrier material is a metal film such as aluminum, which may be provided on one side with a protective layer, e.g. of paper.
The term "nicotine degradation agent barrier" refers to a barrier layer which is substantially impermeable to nicotine degradation agents, such as oxygen and water in liquid or vapor form, and light. The invention may also be defined as a nicotine containment sealing bag comprising:
a) a nitrile rubber modified acrylonitrile-methyl acrylate copolymer nicotine barrier having a volume enclosed therein;
b) a nicotine degradation agent barrier serving to prevent entry of nicotine degradation agents into said volume; and
c) nicotine base within said volume.
Due to the fact that, according to the invention, an active substance solution can be rapidly applied to a matrix layer and is then covered by an active substance impermeable covering layer, it is possible for the first time to obtain in a satisfactory manner well dosed nicotine plasters.
A nicotine plaster produced according to Example 1 after removing the protective layer is immersed in 80 ml of isotonic common salt solution at 37°C C. and the released nicotine quantity is determined liquid chromatographically after predetermined intervals. The release medium volume was chosen in such a way that "sink" conditions are obtained over the entire test period. The following results were obtained:
Nicotine released in vitro per plaster:
after 2 hours: 23.90 mg/plaster
after 4 hours: 32.34 mg/plaster
after 8 hours: 41.50 mg/plaster
after 24 hours: 56.54 mg/plaster
Another nicotine plaster according to the invention may be inventively produced as follows:
A pressure sensitive adhesive material (adhesive 1) comprising 1.9758 kg of a 40% solution of a self-crosslinking acrylate copolymer (DUROTAC 280- 2416 of the firm Delft National & Chemical B.V.) in a mixture of ethyl acetate, ethanol, heptane and methanol, 189.7 g of an acrylic resin of dimethylaminoethylmethacrylate and neutral methacrylate (EUDRAGIT E 100 of the firm RÖHM PHARMA), and 20 g of a mixed acidic triglyceride or fractionated C8-C10 coconut fatty acids (Miglyol 812 of the firm Dynamit Nobel) are applied to a protective layer vapor-deposited with aluminum on one side and abhesively finished on both sides and the solvent is evaporated at 50°C to 80°C C. An approximately 440 g/m2 layer is obtained. From the thus produced pressure sensitive adhesive layer are punched round discs with a diameter of 51 mm. The projecting edges are worked and central to the same is applied in each case one circular disc of a non-woven fabric (fibrous mixture of viscose staple fibre/cotton 70:30 with a substance weight of 40 g/m2--PARATEX III/40 of LOHMANN GMBH & CO KG) and with a diameter of 42 mm. To this is applied nicotine as the active substance in solution (140 g nicotine in 100 g of an acrylic resin of dimethylaminoethylmethacrylate and neutral methacrylates--EUDRAGIT E 100 of the Firm RÖHM PHARMA) in 46 mg doses/disc. The thus produced patches are immediately laminated with a nicotine-impermeable backing layer (a 15 μm thick polyester film, on one side of which aluminum is vapor-deposited having an approximately 110 g/m2 coating of adhesive 1), and sealed in four edge sealing bags of conventional suitable composite packing material.
In this case the non-woven fabric serves as the supporting fabric and to assist the uniform distribution of the nicotine as an inert adjuvant as defined hereinbefore.
Due to the fact that, according to the invention, an active substance solution can be rapidly applied to a matrix layer and is then covered by an active substance impermeable covering layer, it is possible for the first time to obtain in a satisfactory manner well dosed nicotine plasters.
A nicotine plaster produced according to Example 2 after removing the protective layer is immersed in 80 ml of isotonic common salt solution at 37°C C. and the released nicotine quantity is determined liquid chromatographically after predetermined intervals. The release medium volume was chosen in such a way that "sink" conditions are obtained over the entire test period. The following results were obtained:
after 2 hours: 5.1 mg/plaster
after 4 hours: 7.2 mg/plaster
after 8 hours: 10.1 mg/plaster
after 24 hours: 16.5 mg/plaster
It is to be understood that the invention is not limited to nicotine plasters and the production thereof with the claimed build-up but that other substances as preferred substances are mentioned in the specification may be administered by this new therapeutic system.
Patent | Priority | Assignee | Title |
10045759, | Apr 22 2010 | SmartHealth, Inc. | Epicutaneous patch test chamber |
10117453, | Mar 26 2010 | Philip Morris USA Inc. | Inhibition of sensory irritation during consumption of non-smokeable tobacco products |
10201180, | Mar 26 2010 | Philips Morris USA Inc. | Inhibition of undesired sensory effects by the compound camphor |
10653647, | Apr 10 2003 | GRT US HOLDING, INC | Methods and compositions for administration of TRPV1 agonists |
10751267, | Dec 21 2016 | CONOPCO, INC , D B A UNILEVER | Personal care compositions comprising poorly soluble compounds |
10980718, | Dec 21 2016 | Conopco, Inc. | Personal care compositions comprising poorly soluble compounds |
11077039, | Dec 21 2016 | CONOPCO, INC , D B A UNILEVER | Topical skin lightening additive and composition with amino acids and nicotinamide compounds |
11129405, | Mar 26 2010 | Philip Morris USA Inc. | Inhibition of sensory irritation during consumption of non-smokeable tobacco products |
11260005, | Dec 21 2016 | CONOPCO, INC , D B A UNILEVER | Personal care compositions with glutathione precursor comprising 4-substituted resorcinols and amino acids |
11337908, | Dec 21 2016 | CONOPCO, INC , D B A UNILEVER | Personal care compositions with cystine |
11388923, | Mar 26 2010 | Philip Morris USA Inc. | Inhibition of undesired sensory effects by the compound camphor |
11596586, | Dec 21 2016 | Conopco, Inc. | Personal care compositions with glutathione precursor comprising 4-substituted resorcinols and amino acids |
11666519, | Dec 21 2016 | Conopco, Inc. | Personal care compositions with cystine |
11759412, | Dec 21 2016 | Conopco, Inc. | Personal care compositions with glutathione precursor comprising 4-substituted resorcinols and amino acids |
7338673, | May 05 2005 | Medicated patch for treating bee and wasp stings | |
7798976, | Jan 16 2002 | Chemotechnique MB Diagnostics AB | Epicutaneous test plaster |
7857128, | Jul 19 2001 | Philip Morris USA Inc. | Laminated metal foil packaging material and method of making |
7943166, | Apr 10 2003 | GRT US HOLDING, INC | Methods and compositions for administration of TRPV1 agonists |
8263093, | Apr 10 2003 | GRT US HOLDING, INC | Methods and compositions for administration of TRPV1 agonists |
8273390, | Apr 10 2003 | GRT US HOLDING, INC | Methods and compositions for administration of TRPV1 agonists |
8734770, | Apr 10 2003 | GRT US HOLDING, INC | Methods and compositions for administration of TRPV1 agonists |
8783488, | Jul 11 2009 | THINXXS MICROTECHNOLOGY GMBH | Fluid reservoir |
8952038, | Mar 26 2010 | PHILIP MORRIS USA INC | Inhibition of undesired sensory effects by the compound camphor |
9038643, | Mar 26 2010 | PHILIP MORRIS USA INC | Inhibition of sensory irritation during consumption of non-smokeable tobacco products |
9750707, | Apr 10 2003 | GRT US HOLDING, INC | Methods and compositions for administration of TRPV1 agonists |
Patent | Priority | Assignee | Title |
3598122, | |||
3598123, | |||
3731683, | |||
3797494, | |||
4236652, | Mar 20 1979 | American Can Company | Dispenser package |
4286592, | Feb 04 1980 | ALZA Corporation | Therapeutic system for administering drugs to the skin |
4314557, | May 19 1980 | ALZA CORPORATION, A CORP OF CA | Dissolution controlled active agent dispenser |
4379454, | Feb 17 1981 | ALZA Corporation | Dosage for coadministering drug and percutaneous absorption enhancer |
4435180, | May 25 1982 | ALZA CORPORATION, A CORP OF | Elastomeric active agent delivery system and method of use |
4597961, | Jan 23 1985 | NEW MEXICO TECH RESEARCH FOUNDATION, A NON-PROFIT CORP OF MEXICO | Transcutaneous application of nicotine |
4615699, | May 03 1985 | ALZA Corporation | Transdermal delivery system for delivering nitroglycerin at high transdermal fluxes |
4690683, | Jul 02 1985 | Rutgers, The State University of New Jersey | Transdermal varapamil delivery device |
4699792, | Jun 23 1984 | LTS LOHMANN THERAPIE-SYSTEME GMBH & CO KG | Self-adhesive plaster containing medication |
4719226, | Mar 05 1984 | Nitto Electric Industrial Co., Ltd. | Percutaneous absorption type preparation and process for preparing the same |
4769028, | Apr 27 1983 | Lohmann GmbH & Co. KG; Sanol Schwarz GmbH | Pharmaceutical product, in medical bandage form |
4784857, | Jun 03 1986 | Smith and Nephew Associated Companies plc | Drug delivery device, its preparation and use |
4915950, | Feb 12 1988 | Ortho-McNeil Pharmaceutical, Inc | Printed transdermal drug delivery device |
4933184, | Dec 22 1983 | Wyeth | Menthol enhancement of transdermal drug delivery |
5077104, | Dec 21 1989 | ALZA Corporation | Nicotine packaging materials |
5268209, | Dec 21 1989 | ALZA Corporation | Nicotine packaging materials |
6126963, | Aug 28 1986 | LTS Lohmann Therapie-Systeme GmbH & Co. KG | Transdermal therapeutic system, its use and production process |
AU565178, | |||
EP416842, | |||
EP117027, | |||
GB1361289, | |||
WO8505036, |
Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
Feb 03 2000 | LTS Lohmann Therapie-Systeme AG | (assignment on the face of the patent) | / |
Date | Maintenance Fee Events |
Jan 17 2006 | ASPN: Payor Number Assigned. |
Apr 06 2006 | M1552: Payment of Maintenance Fee, 8th Year, Large Entity. |
Apr 09 2010 | M1553: Payment of Maintenance Fee, 12th Year, Large Entity. |
Date | Maintenance Schedule |
Dec 10 2005 | 4 years fee payment window open |
Jun 10 2006 | 6 months grace period start (w surcharge) |
Dec 10 2006 | patent expiry (for year 4) |
Dec 10 2008 | 2 years to revive unintentionally abandoned end. (for year 4) |
Dec 10 2009 | 8 years fee payment window open |
Jun 10 2010 | 6 months grace period start (w surcharge) |
Dec 10 2010 | patent expiry (for year 8) |
Dec 10 2012 | 2 years to revive unintentionally abandoned end. (for year 8) |
Dec 10 2013 | 12 years fee payment window open |
Jun 10 2014 | 6 months grace period start (w surcharge) |
Dec 10 2014 | patent expiry (for year 12) |
Dec 10 2016 | 2 years to revive unintentionally abandoned end. (for year 12) |